Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.

doi:10.1358/dot.2017.53.10.2717625

Back to search

Article

Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.

Drugs of today (Barcelona, Spain : 1998) - 1 Oct 2017

Garcia J S, Percival M E

Abstract excerpt

Midostaurin is a multitargeted tyrosine kinase inhibitor (TKI) that potently inhibits activated fms-related tyrosine kinase 3 (FLT3) in the nanomolar range and other kinases including platelet-derived growth factor receptors α (PDGFR- α) and β (PDGFR- β), cyclin-dependent kinase, proto-oncogene t...

Topics

Adult
Antineoplastic Agents
Clinical Trials as Topic
Drug Interactions
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
Proto-Oncogene Mas
Staurosporine
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.